Responses
Late-Breaking Abstracts
Clinical Trial in Progress
1532 A phase 1/2 study of safety, tolerability, and pharmacokinetics of SNS-101, a pH-sensitive anti-VISTA mAb, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.
